Cargando…

The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia

BACKGROUND: Recent studies suggest that HMG-CoA reductase inhibitors ("statins") may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of statins on mortality for patients hospitalized with community-acquired pneumonia...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortensen, Eric M, Restrepo, Marcos I, Anzueto, Antonio, Pugh, Jacqueline
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1199623/
https://www.ncbi.nlm.nih.gov/pubmed/16042797
http://dx.doi.org/10.1186/1465-9921-6-82
_version_ 1782124882616647680
author Mortensen, Eric M
Restrepo, Marcos I
Anzueto, Antonio
Pugh, Jacqueline
author_facet Mortensen, Eric M
Restrepo, Marcos I
Anzueto, Antonio
Pugh, Jacqueline
author_sort Mortensen, Eric M
collection PubMed
description BACKGROUND: Recent studies suggest that HMG-CoA reductase inhibitors ("statins") may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of statins on mortality for patients hospitalized with community-acquired pneumonia. METHODS: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. RESULTS: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk based on the pneumonia severity index. In the multivariable regression analysis, after adjusting for potential confounders including a propensity score, the use of statins at presentation (odds ratio 0.36, 95% confidence interval 0.14–0.92) was associated with decreased 30-day mortality. DISCUSSION: Prior outpatient statin use was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.
format Text
id pubmed-1199623
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-11996232005-09-09 The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia Mortensen, Eric M Restrepo, Marcos I Anzueto, Antonio Pugh, Jacqueline Respir Res Research BACKGROUND: Recent studies suggest that HMG-CoA reductase inhibitors ("statins") may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of statins on mortality for patients hospitalized with community-acquired pneumonia. METHODS: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. RESULTS: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk based on the pneumonia severity index. In the multivariable regression analysis, after adjusting for potential confounders including a propensity score, the use of statins at presentation (odds ratio 0.36, 95% confidence interval 0.14–0.92) was associated with decreased 30-day mortality. DISCUSSION: Prior outpatient statin use was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect. BioMed Central 2005 2005-07-25 /pmc/articles/PMC1199623/ /pubmed/16042797 http://dx.doi.org/10.1186/1465-9921-6-82 Text en Copyright © 2005 Mortensen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Mortensen, Eric M
Restrepo, Marcos I
Anzueto, Antonio
Pugh, Jacqueline
The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia
title The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia
title_full The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia
title_fullStr The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia
title_full_unstemmed The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia
title_short The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia
title_sort effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1199623/
https://www.ncbi.nlm.nih.gov/pubmed/16042797
http://dx.doi.org/10.1186/1465-9921-6-82
work_keys_str_mv AT mortensenericm theeffectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia
AT restrepomarcosi theeffectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia
AT anzuetoantonio theeffectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia
AT pughjacqueline theeffectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia
AT mortensenericm effectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia
AT restrepomarcosi effectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia
AT anzuetoantonio effectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia
AT pughjacqueline effectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia